Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098021 | 0.90 | HDAC3 (0.44) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL6099710 | 0.90 | HDAC3 (0.44) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL9975271 | 0.80 | HRH3 (0.47) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL9973596 | 0.76 | ALDH1A1 (0.44) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL10811954 | 0.76 | HRH3 (0.41) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL10811950 | 0.76 | HRH3 (0.41) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL5293921 | 0.74 | KEAP1 (0.58) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL3472825 | 0.71 | KEAP1 (0.54) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL12186271 | 0.70 | HRH3 (0.47) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 | |
| SCHEMBL6077013 | 0.70 | HDAC3 (0.56) | HRH3MAPK1ALDH1A1CYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094779-B2 | Piperazine oxime dervatives having NK-1 receptor antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-08-22 | — | — | US | disclosed |
| EP-1406894-B1 | PIPERAZINE OXIME DERIVATIVES HAVING NK-1 RECEPTOR ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2004-12-22 | — | — | EP | disclosed |
| US-20040176389-A1 | Piperazine oxime dervatives having nk-1 receptor antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-09-09 | — | — | US | disclosed |
| EP-1406894-A1 | PIPERAZINE OXIME DERIVATIVES HAVING NK-1 RECEPTOR ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003006459-A1 | PIPERAZINE OXIME DERIVATIVES HAVING NK-1 RECEPTOR ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176389-A1 | Piperazine oxime dervatives having nk-1 receptor antagonistic activity | TACR2, OPRK1, TACR1 | HRH3 261/4885MAPK1 715/4885ALDH1A1 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.